Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06307847
Other study ID # SP-HA-003
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date April 14, 2021
Est. completion date October 25, 2022

Study information

Verified date February 2024
Source Shin Poong Pharmaceutical Co. Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, multicenter, non-inferiority, pivotal clinical trial to assess the efficacy and safety of the novel hexamethylenediamine (HMDA) cross-linked hyaluronate intra-articular injection (SP5M001) compared with an active comparator, the 1,4-butanediol diglycidyl ether (BDDE) cross-linked hyaluronate (Synovian) in patients with knee osteoarthritis.


Recruitment information / eligibility

Status Completed
Enrollment 223
Est. completion date October 25, 2022
Est. primary completion date October 25, 2022
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: 1. Adult males and females aged 40 years or older as of the date of written consent 2. Subject with knee osteoarthritis whose X-ray test results within 6 months from the screening or at the screening visit correspond to grades I - III of the Kellgren & Lawrence scale 3. Subject diagnosed with unilateral or bilateral knee osteoarthritis according to the clinical diagnostic criteria of the American College of Rheumatology (ACR) at screening who have knee joint pain and meet three or more of the following conditions - Over 50 years of age - Less than 30 minutes of morning stiffness ? Crepitus on active motion ? Bony tenderness ? Bony enlargement ? No palpable warmth of synovium 4. Weight bearing pain (WBP) of at least one of both knee joints on 100 mm-VAS = 40 mm when measured at screening and baseline [However, if both sides have symptoms, the knee joint with the higher WBP becomes the joint for evaluation, and the selected joint cannot be changed during the study period.] 5. Walk without relying on a walking aid such as a walker or cane (patients who have been using a walking aid every day since 6 months prior to the screening visit can use the walking aid, and must use the walking aid in the same way throughout the study period.) 6. Ability to fully understand and complete the safety and efficacy measurement questionnaire 7. Voluntary decision for participation and provision of written consent to comply with the precautions after hearing and fully understanding the detailed explanation of the purpose, method, and effects of this study Exclusion Criteria: 1. Body mass index (BMI) = 35 kg/m2 at screening 2. Hip osteoarthritis or osteoarthritis of another joint that is severe enough to preclude evaluation of knee osteoarthritis at the time of screening 3. Having the following diseases that may affect the efficacy and safety evaluation but not being limited to the following - Septic arthritis, rheumatoid arthritis, gout, recurrent pseudogout arthritis, trauma that may damage joint cartilage, congenital abnormalities, calcium deposition disease, diabetes, ochronosis, hemochromatosis, acromegaly, Wilson's disease, primary osteochondrosis, genetic diseases (e.g., hyperkinesis), secondary osteoarthritis caused by collagen gene abnormalities, etc. - Sudek's atrophy or severe painful diseases such as Paget's disease 4. Infection or skin disease in the joint area that is unsuitable for injection at the time of screening - 5) Active or suspected knee joint infection at the time of screening - 6) Complete loss of the Patello-femoral joint space - 7) Received the following treatments within 14 days of the screening visit (except those who have passed a 14-day wash-out) or scheduled to be administered during the study period - Taking medicines containing ingredients such as glucosamine, chondroitin sulfate, and diacerhein - Taking herbal medicines and herbal medicines for osteoarthritis - Taking anti-inflammatory painkillers, non-steroidal anti-inflammatory drugs (NSAIDs, prescription/non-prescription drugs), etc. (administration of acetaminophen allowed if passing a 3 day wash-out) - Taking oral steroids - Hospital physical therapy or oriental medicine treatment (cupping, acupuncture, moxibustion, etc.) 8) Intra-articular injection, such as intra-articular corticosteroid, at the injection site within 6 months from the time of screening 9) Systemic use of steroids within 3 months from the time of screening (including inhalants, however, topical application is permitted only on the upper body) 10) Hyaluronic acid intra-articular injection administered to the injection site within 6 months from the time of screening 11) Surgical operations such as knee joint replacement, including arthroscopic surgery, at the administration site within 6 months from the time of screening; or expecting surgery within 10 months 12) History of artificial joint surgery on the knee joint subject for evaluation 13) Knee joint subject for evaluation diagnosed as Kellgren Lawrence grade 4 within 6 months from the time of screening 14) Moderate or severe joint effusion by Patella tap test at the screening visit 15) History of hypersensitivity to ingredients of the IP or active control drug 16) Antiplatelet agents (excluding aspirin of 300 mg/day or less), heparin, oral anticoagulants (coumarin anticoagulants, thrombin inhibitors, Factor Xa inhibitors, etc.), and thrombolytics must be used during the study 17) Clinically significant abnormalities in liver function (3 times or more than the upper limit of normal for ALT/AST) or abnormalities in renal function (3 times or more than the upper limit of normal for serum creatinine), or severe liver or renal disease at the discretion of the investigator which is judged to have an impact on the effectiveness and safety evaluation of the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SP5M001 inj
pre-filled syringe
Synovian inj
pre-filled syringe

Locations

Country Name City State
Korea, Republic of Yeungnam University Medical Center Daegu
Korea, Republic of Cheonam National University Hwasun Hospital Hwasun
Korea, Republic of Gachon University Gil Medical Center Incheon
Korea, Republic of Jeonbuk National University Hospital Jeonju
Korea, Republic of Chungnam National University Hospital Sejong
Korea, Republic of Seoul National University Bundang Hospital Seongnam-si
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Chung-ang University Hospital Seoul
Korea, Republic of Kyung Hee University Hospital at Gangdong Seoul
Korea, Republic of Kyunghee University Hospital Seoul
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of Soon Chun Hyang University Hospital Seoul Seoul
Korea, Republic of The Catholic University of Korea, Seoul St. Mary's Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Shin Poong Pharmaceutical Co. Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Other The incidence rate of Pre-treatment AEs From week 0 to week 36
Other The incidence rate of Solicited Local AEs From week 0 to week 36
Other The incidence rate of treatment-emergent adverse event (TEAE) From week 0 to week 36
Other The incidence rate of Serious TEAEs From week 0 to week 36
Other The incidence rate of Serious TEAEs leading to Drug withdrawn From week 0 to week 36
Other The incidence rate of Serious TEAEs leading to Death From week 0 to week 36
Other The incidence rate of abnormal CS at Post-Treatment on Laboratory From week 0 to week 36
Other The incidence rate of abnormal CS at Post-Treatment on Electrocardiogram From week 0 to week 36
Other The incidence rate of abnormal on Physical Examination From week 0 to week 36
Primary Change in [Weight-Bearing Pain (WBP)-100mm-visual analogue scale (VAS)] at Week 12 from baseline (visit 2) * Weight Bearing Pain (WBP) - 100mm-visual analogue scale (VAS) week 12
Secondary Changes in the following at each visit : Weight Bearing pain(WBP) (Weeks 2, 6, 24, and 36) from baseline (Visit 2) Outcome Measurement of Weight Bearing pain(WBP): 100mm-visual analogue scale (VAS) week 2, 6, 24, 36
Secondary Changes in the following at each visit : Rest pain (RP) (Weeks 2, 6, 12, 24, and 36) from baseline (Visit 2) Outcome Measurement of Rest pain (RP): 100mm-visual analogue scale (VAS) week 2, 6, 12, 24, 36
Secondary Changes in the following at each visit : Night pain (NP) (Weeks 2, 6, 12, 24, and 36) from baseline (Visit 2) Outcome Measurement of Night pain (NP): 100mm-visual analogue scale (VAS) week 2, 6, 12, 24, 36
Secondary Changes in the following at each visit : Motion pain (MP) (Weeks 2, 6, 12, 24, and 36) from baseline (Visit 2) Outcome Measurement of Motion pain (MP): 100mm-visual analogue scale (VAS) week 2, 6, 12, 24, 36
Secondary Changes in the following at each visit : Patient Global Assessment(PGA) (Weeks 2, 6, 12, 24, and 36) from baseline (Visit 2) Outcome Measurement of Patient Global Assessment(PGA): 100mm-visual analogue scale (VAS) week 2, 6, 12, 24, 36
Secondary Changes in the following at each visit : Investigator Global Assessment (IGA) (Weeks 2, 6, 12, 24, and 36) from baseline (Visit 2) Outcome Measurement of Investigator Global Assessment (IGA) : 100mm-visual analogue scale (VAS) week 2, 6, 12, 24, 36
Secondary Changes in the following at each visit : Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total score and individual score evaluation (Pain, function, stiffness) (Weeks 2, 6, 12, 24, and 36) from baseline (Visit 2) Outcome Measurement of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total score and individual score evaluation (Pain, function, stiffness)
: WOMAC-Likert Assessment (5-point Likert scale)
week 2, 6, 12, 24, 36
Secondary Physical assessments at each post-administration visit: Swelling (Weeks 2, 6, 12, 24, and 36) Outcome Measurement of Swelling: 4-point scale
*4-point scale: 0(none)/1(mild)/2(moderate)/3(severe)
week 2, 6, 12, 24, 36
Secondary Physical assessments at each post-administration visit: joint-line tenderness on pressure (Weeks 2, 6, 12, 24, and 36) Outcome Measurement of joint-line tenderness: 4-point scale
*4-point scale: 0(none)/1(mild)/2(moderate)/3(severe)
week 2, 6, 12, 24, 36
Secondary Physical assessments at each post-administration visit: range of motion (Weeks 2, 6, 12, 24, and 36) The angle was recorded as is for the range of motion. week 2, 6, 12, 24, 36
Secondary Proportion of participants who took rescue medication at each post-administration visit and dose of rescue medication (Weeks 2, 6, 12, 24, and 36) week 2, 6, 12, 24, 36
Secondary Post-administration response rate A. Proportion at which WBP decreases by at least 20 mm or improves by at least 40% from baseline at the time of evaluation (B section-Description) *B. Response rate of OMERACT-OARSI (Outcome Measures in Rheumatology-Osteoarthritis Research Society International) I. At least 50% improvement in WOMAC pain or function at the time of evaluation; or at least a 20 point improvement from baseline; or II. meeting 2 of the 3 conditions below
At least 20% improvement in WOMAC pain, at least a 10 point improvement from each baseline
At least 20% improvement in WOMAC function, at least a 10 point improvement from each baseline
At least 20% improvement in patient's global assessment (100 mm-VAS) and at least a 10 point improvement from each baseline
week 2, 6, 12, 24, 36
See also
  Status Clinical Trial Phase
Completed NCT04875156 - The Angle of the Metacarpophalangeal Joint of the Thumb During Maximal Pinch Strength N/A
Completed NCT03687775 - CMC I Stability Intraoperative
Recruiting NCT03196310 - Single Blinded First CMC Osteoarthritis Treatment N/A
Completed NCT05650970 - Radial Nerve Mobilization in Hand Thumb Osteoarthritis Patients N/A
Recruiting NCT06084364 - Intraarticular Steroids, Saline and Occupational Therapy in People With CMC1 Osteoarthritis Phase 4
Active, not recruiting NCT03200886 - Comparison of the Efficacy of Intra-articular Hybrid Hyaluronic Acid and Steroid in Patients With Rizoarthrosis N/A
Not yet recruiting NCT06370312 - Analysis of Articular Biomarkers From Osteoarthritic Thumb Basal Joints
Completed NCT03622736 - Influence of the Radiological Stage on the Efficiency of Viscosupplementation in Basal Thumb Arthritis
Completed NCT05275244 - Evaluate Clinical Benefit of Local Treatment With KD Intra-Articular® Gel in Patients With Osteoarthritis (NO-DOLOR2)
Recruiting NCT04458584 - Restoration of Thumb Strength and Function in Basal Joint Arthritis: A Comparative Effectiveness Trial (RESTART)
Completed NCT05849506 - Touch on One Thumb, RSI on the Other Thumb: Which Surgery Shows Better Results
Recruiting NCT06459063 - Intra-articular Allocetra in Osteoarthritis of the 1st Carpo-metacarpal Joint Phase 1/Phase 2
Recruiting NCT06193499 - A Study on the Effect of High-concentrated Platelet Rich Plasma (PRP) on Osteoarthritis in the Thumb Base. N/A
Recruiting NCT03815734 - Effects of Motor Imagery on Trapeziometacarpal Osteoarthritis in Women During the Postoperative Immobilization Period N/A
Active, not recruiting NCT04391751 - Concomitant Basal Joint Arthroplasty and Carpal Tunnel Release N/A
Not yet recruiting NCT03327480 - The Effects of Two Different Orthosis on Pain, Hand Strength and Function in Patients With Thumb Carpometacarpal Osteoarthritis N/A
Recruiting NCT04676802 - Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone Phase 2
Recruiting NCT04217928 - Arthroscopic Debridement vs Arthroscopic Hemi-Trapeziectomy on Patients With Thumb Carpometacarpal Joint Osteoarthritis N/A
Recruiting NCT06151834 - Prospective Study of Arthrodesis of Finger Distal Interphalangeal Joints Using the Kerifuse Device N/A
Recruiting NCT05932628 - Thumb Osteoarthritis Prognosis for Supported Self-managment